It is plausible to speculate that TRPC3 inhibition might be instrumental in blocking excessive renal water retention during the clinically relevant states associated high AVP levels, such as congestive heart failure or syndrome of inappropriate AVP secretion [1]. The gene discussed is TRPC3; the disease is congestive heart failure.